Resultados de Búsqueda
The use of beta-agonists is not recommended in adult patients with acute respiratory distress syndrome.
Evidencias COVID-19
Cochrane - Colección Especial - cuidados críticos (tratamiento farmacológico)
Beta-agonists are likely to slightly increase early mortality by 40 per 1,000 patients (with up to 119 more deaths or 25 fewer); however, the 95% CI includes the possibility of an increase as well as a reduction in mortality (RR 1.14, 95% CI 0.91 to 1.42; three studies, 646 participants; evidence of moderate certainty) ). Due to very low certainty evidence, it is not known for certain whether beta-agonists increase days without ventilation (DM ‐2.20, 95% CI ‐3.68 to ‐0.71; three studies, ...
ver más ... 2019The use of statins is not recommended in adult patients with acute respiratory distress syndrome to decrease the duration of mechanical ventilation.
Evidencias COVID-19
Cochrane - Colección Especial - cuidados críticos (tratamiento farmacológico)
Statins may result in little or no difference in the duration of mechanical ventilation (MD 2.70, 95% CI ‐3.55 to 8.95; one study, 60 participants; evidence of low certainty). Three studies reported the number of ventilator‐free days up to day 28 for 1342 participants. The found that statins probably make little or no difference to the number of ventilator‐free days up to day 28 (MD 0.40 days, 95% CI −0.71 to 1.52; I2 = 0%; moderate‐certainty evidence
ver más ... 2019The use of surfactants is not recommended to reduce the duration of mechanical ventilation in adult patients with acute respiratory distress syndrome.
Evidencias COVID-19
Cochrane - Colección Especial - cuidados críticos (tratamiento farmacológico)
It is not known whether surfactants reduce the duration of mechanical ventilation (DM ‐2.50, 95% CI ‐4.95 to ‐0.05, one study, 16 participants). Six studies reported the number of ventilator‐free days up to day 28 for 856 participants. They found little or no difference between participants given surfactants or a control for this outcome in two studies (MD −0.39, 95% CI −2.49 to 1.72; I2 = 0%; 344 participants; very low‐certainty evidence).
ver más ... 2019Reliable information on the use of surfactants in adult patients with acute respiratory distress syndrome to decrease mortality is not available.
Evidencias COVID-19
Cochrane - Colección Especial - cuidados críticos (tratamiento farmacológico)
It is not known for certain whether surfactants result in little or no difference in early mortality (RR 1.08, 95% CI 0.91 to 1.29; nine studies, 1338 participants) or if they reduce late mortality. from all causes (RR 1.28, 95% CI 1.01 to 1.61; one study, 418 participants).
ver más ... 2019The use of steroids is recommended to decrease the number of days that adult patients with acute respiratory distress syndrome require mechanical ventilation (days without ventilation until day 28).
Evidencias COVID-19
Cochrane - Colección Especial - cuidados críticos (tratamiento farmacológico)
Four studies reported duration of mechanical ventilation for 368 participants. One study reported a shorter duration of mechanical ventilation in the corticosteroids group (median 5 days (interquartile range (IQR) 3 to 8 days) compared to the control group (median 9.5 days (IQR 6 to 9.5 days): P = 0.002). In the remaining three studies, no found evidence of a difference between groups in duration of mechanical ventilation (MD −4.30 days, 95% CI −9.72 to 1.12; I2 = 93%; 277 participants; ...
ver más ... 2019